Captixbio is a pioneering biomedical company developing an implantable solution enabling long term, life-enhancing outcomes from cell therapies. Captixbio's IMITA will cure Type 1 diabetes by addressing the limitations of existing, unapproved, cell based strategies and cost-effectively removing the daily burden of insulin administration and the fear of maintaining glucose control whilst eliminating lifelong, immuno-suppression therapy.